These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21968939)

  • 21. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
    Yoo J; Park SS; Lee YJ
    J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
    Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
    Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
    Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
    Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
    J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
    J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
    Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
    Wen X; Li X; Liao B; Liu Y; Wu J; Yuan X; Ouyang B; Sun Q; Gao X
    Urology; 2009 Jun; 73(6):1407-11. PubMed ID: 19362342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
    Li L; Zhu Z; Joshi B; Porter AT; Tang DG
    Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
    Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
    Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
    Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
    Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
    Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
    Wu JD; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Plymate SR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6153-60. PubMed ID: 17062692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.